Cancer Biomarkers Market Size, Growth, Demands Outlook and Forecasts to 2030

According to the research report, the global cancer biomarkers market size is expected to touch USD 32.09 Billion by 2030, from USD 12.03 Billion in 2022, growing with a significant CAGR of 13% from 2022 to 2030. 

The cancer biomarkers report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global cancer biomarkers in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global cancer biomarkers market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global cancer biomarkers during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1637

 Report Scope of the Cancer Biomarkers Market

Report Coverage	Details
Market Size by 2030	USD 32.09 Billion
Growth Rate from 2022 to 2030	CAGR of 13%
Largest Market	North America
Fastest Growing Market	Asia Pacific
Base Year	2021
Forecast Period	2022 to 2030
Segments Covered	Type, Biomolecule, Profiling Technology, End User, Application, Region

This study covers a detailed segmentation of the global cancer biomarkers market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global cancer biomarkers market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• Abbott Laboratories
• Exact Sciences
• Meso Scale Diagnostics LLC
• Seegene Technologies Inc.
• Siemens Healthineers

Market Segmentation

 By Type

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Liver Cancer
• Lung Cancer
• Others

By Biomolecule

• Genetic Biomarkers
• Epigenetic Biomarkers
• Metabolic Biomarkers
• Proteomic Biomarkers
• Others

By Application

• Drug Discovery and Development
• Diagnostics
• Personalized Medicine
• Others

By Profiling Technology

• Omic Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics-based Tests

By End User

• Hospitals
• Academic and Cancer Research Institutes
• Ambulatory Surgical Centres
• Diagnostic Laboratories

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa

Research Methodology

The research methodology adopted by analysts for compiling the global cancer biomarkers report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global cancer biomarkers market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Biomarkers Market 

5.1. COVID-19 Landscape: Cancer Biomarkers Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Biomarkers Market, By Type

8.1. Cancer Biomarkers Market, by Type, 2022-2030

8.1.1. Breast Cancer

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Prostate Cancer

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Colorectal Cancer

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Cervical Cancer

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Liver Cancer

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Lung Cancer

8.1.6.1. Market Revenue and Forecast (2017-2030)

8.1.7. Others

8.1.7.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Cancer Biomarkers Market, By Biomolecule Type

9.1. Cancer Biomarkers Market, by Biomolecule Type, 2022-2030

9.1.1. Genetic Biomarkers

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Epigenetic Biomarkers

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Metabolic Biomarkers

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Proteomic Biomarkers

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Cancer Biomarkers Market, By Application Type 

10.1. Cancer Biomarkers Market, by Application Type, 2022-2030

10.1.1. Drug Discovery and Development

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Diagnostics

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Personalized Medicine

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Cancer Biomarkers Market, By Profiling Technology

11.1. Cancer Biomarkers Market, by Profiling Technology Type, 2022-2030

11.1.1. Omic Technologies

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Imaging Technologies

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Immunoassays

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Cytogenetics-based Tests

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Cancer Biomarkers Market, By End User Type

12.1. Cancer Biomarkers Market, by End User, 2022-2030

12.1.1. Hospitals

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Academic and Cancer Research Institutes

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Ambulatory Surgical Centres

12.1.3.1. Market Revenue and Forecast (2017-2030)

12.1.4. Diagnostic Laboratories

12.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Cancer Biomarkers  Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Type (2017-2030)

13.1.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.1.3. Market Revenue and Forecast, by Application (2017-2030)

13.1.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.1.5. Market Revenue and Forecast, by End User (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Type (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.1.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.1.7. Market Revenue and Forecast, by End User (2017-2030) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Type (2017-2030)

13.1.8.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.1.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.1.8.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.1.8.5. Market Revenue and Forecast, by End User (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Type (2017-2030)

13.2.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.2.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.4. Market Revenue and Forecast, by Profiling Technology (2017-2030) 

13.2.5. Market Revenue and Forecast, by End User (2017-2030) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Type (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.2.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.7. Market Revenue and Forecast, by Profiling Technology (2017-2030) 

13.2.8. Market Revenue and Forecast, by End User (2017-2030) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Type (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.2.9.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.10. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.2.11. Market Revenue and Forecast, by End User (2017-2030)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Type (2017-2030)

13.2.12.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.2.12.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.12.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.2.13. Market Revenue and Forecast, by End User (2017-2030)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Type (2017-2030)

13.2.14.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.2.14.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.14.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.2.15. Market Revenue and Forecast, by End User (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Type (2017-2030)

13.3.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.3.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.3.5. Market Revenue and Forecast, by End User (2017-2030)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Type (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.3.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.3.7. Market Revenue and Forecast, by End User (2017-2030)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Type (2017-2030)

13.3.8.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.3.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.3.9. Market Revenue and Forecast, by End User (2017-2030)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Type (2017-2030)

13.3.10.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.3.10.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.10.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.3.10.5. Market Revenue and Forecast, by End User (2017-2030)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Type (2017-2030)

13.3.11.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.3.11.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.11.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.3.11.5. Market Revenue and Forecast, by End User (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Type (2017-2030)

13.4.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.4.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.4.5. Market Revenue and Forecast, by End User (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Type (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.4.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.4.7. Market Revenue and Forecast, by End User (2017-2030)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Type (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.4.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.4.9. Market Revenue and Forecast, by End User (2017-2030)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Type (2017-2030)

13.4.10.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.4.10.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.10.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.4.10.5. Market Revenue and Forecast, by End User (2017-2030)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Type (2017-2030)

13.4.11.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.4.11.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.11.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.4.11.5. Market Revenue and Forecast, by End User (2017-2030)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Type (2017-2030)

13.5.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.5.3. Market Revenue and Forecast, by Application (2017-2030)

13.5.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.5.5. Market Revenue and Forecast, by End User (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Type (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.5.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.5.7. Market Revenue and Forecast, by End User (2017-2030)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Type (2017-2030)

13.5.8.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.5.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.5.8.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.5.8.5. Market Revenue and Forecast, by End User (2017-2030)

Chapter 14. Company Profiles

14.1. F. Hoffmann-La Roche Ltd.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Thermo Fisher Scientific Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. QIAGEN N.V.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Illumina Inc.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Bio-Rad Laboratories Inc.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Abbott Laboratories

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Exact Sciences

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Meso Scale Diagnostics LLC

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Seegene Technologies Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Siemens Healthineers

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com